Nonspecific symptoms dominate at first contact to emergency healthcare services among cases with invasive meningococcal disease

Nichlas Hovmand1,2*, Helle Collatz Christensen2,3, Lene Fogt Lundbo1, Håkon Sandholdt1, Gitte Kronborg4, Perle Darsø5, Jacob Anhøj6, Stig Nikolaj Fasmer Blomberg2,3, Asmus Thun Bisgaard3 and Thomas Benfield1,2

Abstract
Background: An early appropriate response is the cornerstone of treatment for invasive meningococcal disease. Little evidence exists on how cases with invasive meningococcal disease present at first contact to emergency medical services.

Methods: Retrospective observational study of cases presenting with invasive meningococcal disease from January 1st of 2016 to December 31st of 2020 in the Capital Region of Denmark with a catchment area population of 1,800,000. A single medical emergency center provides services to the region. Data was collected from emergency medical services’ call audio files, data from the call receiver registrations, registrations from ambulance personal and electronic health record data from the hospitalization.

Results: Of 1527 cases suspected of meningitis, 38 had invasive meningococcal disease and had been in contact with the emergency service. Most contacts were to the medical helpline rather than the emergency call center at initial contact to emergency medical services. All were hospitalized within 12 h. At initial contact, fever was present in 28 (74%) of 38 cases, while specific symptoms such as headache (n=12 (32%)), a rash or petechiae (n=9 (23%)) and stiffness of the neck (n=4 (11%)) varied and were infrequent. Cases younger than 18 years of age were more often male and more often presented with fever and rash/petechiae. Only 4 (11%) received prehospital antibiotic treatment.

Conclusions: Cases with invasive meningococcal disease presented with fever and unspecific symptoms. Although few were acutely ill at their initial contact, all were admitted within 12 h. We suggest that all feverish cases should be systematically asked about specific symptoms and should be wary of symptom progression to optimize the early management if cases with invasive meningococcal disease.

Keywords: Infection, Emergency care systems, Prehospital care, Meningitis

Background
Currently, little evidence exists about prehospital identification and management of cases with invasive meningococcal disease (IMD) and most of the current literature is centered around timing and administration of antibiotics [1]. The evidence for other prehospital interventions for IMD is scarce. Reports on symptoms have focused...
on specific symptoms such as fever, rashes or meningeal symptoms, while other early symptoms that have been reported in children, such as leg pain, have not been assessed in adult patients [2, 3]. A study of early symptoms in young infants with bacterial meningitis (BM) indicated that non-specific features associated with bacterial meningitis rarely progressed from onset to admission [4]. Similar studies among non-neonatal cases and cases with IMD are needed.

IMD remains a significant global burden of disease, even though effective treatment is widely available [5–8]. IMD presenting as sepsis is more lethal than when presenting as meningitis [9]. Classical features of meningococcal sepsis include a characteristic petechial rash in affected cases with fever, but the early symptoms of the disease are often nonspecific, thus making an early diagnosis difficult [10, 11]. Lack of early recognition of the disease can within a matter of hours lead to a significantly increased risk of death or permanent injury [6, 11]. 85% of deaths from IMD has been reported to occur within 24 h from diagnosis [12]. More knowledge about early symptoms of IMD is needed to increase the number of cases who receive treatment early.

In the Capital Region of Denmark contact to the emergency medical services (EMS) generally follows two paths. One contact telephone number is for absolute medical emergencies that receives 130,000 health related annual calls. The other telephone contact number is to a medical helpline staffed by a registered specialist nurse that receives 950,000 annual calls. The region’s guideline for prehospital handling of cases suspected of IMD is that an ambulance and a medical doctor should be sent to the case immediately and if IMD is suspected, antibiotics should be administered on site.

Here we report information about symptoms presenting in IMD cases at the first contact to EMS.

Methods
Case identification
This is a retrospective observational study of cases presenting with IMD from January 1st of 2016 to December 31st of 2020 in the Capital Region of Denmark with a catchment area population of 1,800,000. The Committee on Health Research Ethics were not involved in approving the study as this was a quality development project. Permission to collect data from case records was granted by Center for Health and by Emergency Medical Services in the Capital Region of Denmark as required by Danish legislation [13].

All Danish residents have a unique personal identification number permitting linkage to national health registries. Eligible cases were identified by assessing all diagnosis codes of meningitis (International Classification of Disease, 10th edition, (ICD-10) codes: DG00* or IMD (ICD-10: DA39*) in electronic health records (EHR). Further, the databases of the region's clinical microbiology services were reviewed, as patients with any positive finding in a sample of cerebrospinal fluid and all patients with a positive finding of meningococci from any anatomical location were added to the list of potential cases to be screened. Each case's EHR was reviewed by a physician.

Data collection
Data sources included EMS call audio files, data from the call receiver registrations, registrations from ambulance personal and EHR data from each individual hospitalization. All audio files and records were abstracted by a physician. It was noted whether a symptom was mentioned or if the symptom was present during the conversation or registered by ambulance personal.

Data on treatment initiation prior to hospitalization were gathered from ambulance registrations and/or EHRs, while data on age, gender, time to initiation of relevant treatment during hospitalization and on 30-day mortality were gathered from EHRs. Data on serogroups and sites of infection were gathered from a database containing all clinical microbiological tests in the Capital Region of Denmark.

Statistical analysis
Values are presented as median and interquartile ranges or proportions and percentages. Correlations were calculated using Spearman’s rank correlation coefficient. P-values for differences between age groups were calculated using Fisher’s Exact Test. Two-sided P values of less than 0.05 were considered statistically significant. Statistics were done in R version 3.6.0. Because symptoms were not always asked about, P values are presented for both symptom present in cases asked about that symptom and symptom present in all cases. P values are reported as crude values not adjusted for multiple comparisons.

Results
Case characteristics
A total of 1527 potential cases were identified; 548 cases by ICD-10 codes and 979 identified through clinical microbiology databases. Each case’s EHR was evaluated. Forty-three cases had confirmed IMD. Five had no contact to the EMS prior to hospitalization. The remaining 38 cases were included for analysis (Fig. 1). Thirty-five cases were confirmed by culture while 3 cases were confirmed by polymerase chain reaction.

The cases were evenly distributed over the 5-year period, except for 2020 where there were fewer cases (Table 1). The median age was 20 years, and 22 (58%)
Fig. 1  Flow chart of case identification, inclusion and exclusion. This flow chart illustrates the sources that cases were identified from and reasons for exclusion. Following this process, 38 cases with invasive meningococcal disease who had contact to emergency medical services prior to hospitalization between 2016 and 2020 in the Capital Region of Denmark were included in analysis.

Table 1  Case characteristics

|                        | All N = 38 | Age <18 years N = 17 | Age ≥18 years N = 21 | p-value |
|------------------------|------------|----------------------|----------------------|---------|
| Age (years)            |            |                      |                      |         |
| - Median (interquartile range) | 20 (5 and 61) | 3 (1 and 16) | 60 (37 and 77) |         |
| Gender                 |            |                      |                      |         |
| - Female               | 16 (42%)   | 2 (12%)              | 14 (67%)             | <0.01   |
| - Male                 | 22 (58%)   | 15 (88%)             | 7 (33%)              |         |
| Site of infection      |            |                      |                      |         |
| - Meningitis           | 8 (21%)    | 5 (29%)              | 3 (14%)              | 0.43    |
| - Meningitis and sepsis| 10 (26%)   | 5 (29%)              | 5 (24%)              | 0.72    |
| - Sepsis               | 20 (53%)   | 7 (41%)              | 13 (62%)             | 0.32    |
| Serogroup              |            |                      |                      |         |
| - B                    | 12 (32%)   | 8 (47%)              | 4 (19%)              | 0.09    |
| - C                    | 5 (13%)    | 2 (12%)              | 3 (14%)              | 1.00    |
| - W                    | 10 (26%)   | 2 (12%)              | 8 (38%)              | 0.14    |
| - Y                    | 8 (21%)    | 3 (18%)              | 5 (24%)              | 0.71    |
| - Unknown              | 3 (8%)     | 2 (12%)              | 1 (5%)               | 0.58    |
| Year at disease        |            |                      |                      |         |
| - 2016                 | 8 (21%)    | 2 (12%)              | 6 (29%)              | 0.26    |
| - 2017                 | 8 (21%)    | 4 (24%)              | 4 (19%)              | 0.69    |
| - 2018                 | 11 (29%)   | 8 (47%)              | 3 (14%)              | 0.02    |
| - 2019                 | 8 (21%)    | 2 (12%)              | 6 (29%)              | 0.26    |
| - 2020                 | 3 (8%)     | 1 (6%)               | 2 (10%)              | 1.00    |
| Emergency service used |            |                      |                      |         |
| - 112: Emergency call center | 13 (34%) | 3 (18%) | 10 (47%) | 0.08 |
| - 1813: Medical helpline | 25 (66%) | 14 (82%) | 11 (53%) | 0.31 |
| 30-day mortality       |            |                      |                      |         |
| - Survivor             | 34 (89%)   | 14 (82%)             | 20 (95%)             |         |
| - Non-survivor         | 4 (11%)    | 3 (18%)              | 1 (5%)               |         |

List of case characteristics of the 38 cases with invasive meningococcal disease who had contact to emergency medical services prior to hospitalization between 2016 and 2020 in the Capital Region of Denmark. Cases are grouped as either children under 18 years of age or adults. Children were more likely to be male while adults were more likely to be female. In 2018 there were more children compared to adults. No other differences between the age groups were significant.
were male. Twenty (53%) had sepsis, 8 (21%) had meningitis, and 10 (26%) had sepsis and meningitis. Twelve (32%) were infected with serogroup B, 5 (26%) with C, 10 (26%) with W, 8 (21%) with Y and 3 (8%) with an unknown serogroup. Serogroup B was the most common in children while serogroup W was the most common in adults (Table 1). Thirteen (34%) initially contacted the emergency call center, while the medical helpline was the first contact for 25 (66%).

Cases younger than 18 years of age were more often male, while those older than 18 were more often female (Table 1, p<0.01). In 2018, more cases were younger than 18 years of age than older (p=0.02). There were no other significant differences between the age groups regarding site of infection, serogroup, year of disease, emergency service used or 30-day mortality.

**Symptoms at initial contact to EMS**

At least one symptom was mentioned in each call but in no call all symptoms were mentioned (Table 2). The most common symptom was fever that was present in 28 of the 30 cases that were asked about or mentioned it during the call followed by fatigue (20 of 23). Specific symptoms associated with IMD or meningitis were not as often confirmed to be present during the initial contact: headache (12 of 14), altered mental state (10 of 26), leg pain (9 of 10), rash or petechiae (9 of 18), stiffness of the neck (4 of 12) and photophobia (1 of 1). Children and adolescents were significantly more likely to present with fever and rash/petechiae compared to adults who often a difficulty breathing.

Of the 18 cases asked about or mentioning both fever and a rash or petechiae, 9 cases presented both. Of the 8 cases asked about or mentioning both fever, headache, and stiffness of the neck, 2 cases presented all three symptoms. The highest paired correlations were seen between headache and vomiting (r=0.63, CI95%: [0.40;0.79], p<0.01), difficulty breathing and chest pain (r=0.49, CI95%: [0.20;0.70], p=0.27) and fatigue and altered mental state (r=0.45, CI95%: [0.14;0.67], p=0.73) (Fig. 2).

**Prehospital management**

From the 38 initial phone calls, 8 cases were suspected of IMD by the call receiver (Fig. 3). All 8 were seen prehospitaly by a medical doctor and 4 of the cases received antibiotics on site. Of the remaining 4 cases, 3 were taken to the hospital while 1 was asked to stay at home.

**Table 2 Symptoms at initial call to emergency medical services**

| Symptom present / symptom asked about | p-value | present of asked about | present of all cases |
|--------------------------------------|---------|------------------------|---------------------|
|                                      |         | All cases N = 38       | Age <18 years N = 17 | Age ≥18 years N = 21 |
| Fever                               | 26 of 30| 16 of 17               | 12 of 13            | 1.00                | 0.01 |
| Fatigue                             | 20 of 23| 11 of 14               | 9 of 9              | 0.25                | 0.21 |
| Headache                            | 12 of 14| 6 of 8                 | 6 of 6              | 0.47                | 0.73 |
| Vomiting                            | 12 of 18| 6 of 9                 | 6 of 9              | 1.00                | 0.73 |
| Upper airway symptoms               | 10 of 16| 5 of 8                 | 5 of 8              | 1.00                | 0.73 |
| Difficulty breathing                | 10 of 19| 1 of 5                 | 9 of 14             | 0.14                | 0.01 |
| Altered mental state                | 10 of 26| 5 of 13                | 5 of 13             | 1.00                | 0.73 |
| Leg pain                            | 9 of 10 | 4 of 5                 | 5 of 5              | 1.00                | 1.00 |
| Rash and/or petechiae               | 9 of 18 | 9 of 15                | 0 of 3              | 0.21                | <0.01|
| Tremors and/or seizures             | 7 of 7  | 2 of 2                 | 5 of 5              | 1.00                | 0.43 |
| Diarrhea                            | 6 of 7  | 2 of 2                 | 4 of 5              | 1.00                | 0.67 |
| Stiffness of the neck               | 4 of 12 | 3 of 9                 | 1 of 3              | 1.00                | 0.31 |
| Chest pain                          | 3 of 6  | 0 of 0                 | 3 of 6              | 1.00                | 0.24 |
| Abdominal pain                      | 3 of 6  | 0 of 1                 | 3 of 5              | 1.00                | 0.24 |
| Spinal urination                    | 2 of 6  | 0 of 3                 | 2 of 3              | 0.40                | 0.49 |
| Photophobia                         | 1 of 1  | 1 of 1                 | 0 of 0              | 1.00                | 0.45 |
| Endangered airway                   | 1 of 4  | 0 of 1                 | 1 of 3              | 1.00                | 1.00 |
| Stroke-symptoms                     | 1 of 4  | 0 of 0                 | 1 of 4              | 1.00                | 1.00 |

*List of symptoms mentioned in 38 initial phone calls to emergency medical services. Thirteen calls were to the emergency call center 112, while 25 were to the medical helpline 1813. For any symptom, it was registered in how many calls the symptom was present and in how many calls the symptom was asked about and/or mentioned. Because symptoms were not always asked about, p-values are presented for both symptom present in cases asked about and symptom present in all cases. There was no difference between children and adults in symptoms present of symptoms asked about, but of all cases, children more often presented with fever and rash/petechiae than adults.*
None of the 30 cases not suspected of IMD during the phone call received prehospital antibiotics. A single case was seen prehospitaly by a medical doctor and was then taken to the hospital. Ambulances were sent to 13 of the 30 cases and they were all taken to the hospital. Of the remaining 16 cases that were not seen prehospitaly, 11 were asked to transport themselves to the hospital while 5 were asked to stay at home after the initial phone call. Those 5 cases all were hospitalized within 6h, as one went to the hospital by own transportation, one called the medical helpline again and three called the emergency call center.

All 38 cases were hospitalized one way or another within 12h from the initial phone call.

**Hospital management and outcome**

Of the 34 cases that arrived at the hospital without having received antibiotics prehospitaly, 10 were suspected of IMD at the first evaluation and treated as such with an average time to initiation of relevant treatment of 2h (Fig. 4). Relevant treatment was defined as treatment against a known etiology or empirical treatment as per local guideline for suspected IMD or BM.

Thus, 24 cases were not suspected of IMD at first evaluation at the hospital and 10 of these initially received other antibiotic treatment before they received relevant treatment after an average of 31h. A single case in this group did not survive. Thirteen cases not suspected of IMD did not receive other antibiotic treatment before initiation of relevant treatment after an average of

![Fig. 2](image.png)
Fig. 3 Flow chart of prehospital management of cases with invasive meningococcal disease. Thirty-eight cases who had invasive meningococcal disease (IMD) called emergency medical services prior to hospitalization. This flow chart illustrates how cases were handled prehospitaly. Four of the 38 cases received antibiotics on site after evaluation from a medical doctor as per the region’s guideline (green). Seventeen cases were transported to a hospital by an ambulance but did not receive treatment (yellow). Eleven cases were asked to go to the hospital by own transportation (orange). Six cases were asked to stay home (red). All 38 cases were hospitalized by one way or another within 12h.

Fig. 4 Flow chart of hospital management of cases with invasive meningococcal disease. Thirty-four cases who had invasive meningococcal disease (IMD) arrived at a hospital without being treated prehospitaly. Ten were suspected of IMD at first evaluation and treated as such. Twenty-four cases were not suspected of IMD at first evaluation. Ten of these initially received other antibiotic treatment while 13 did not receive other antibiotic treatment before initiation of relevant treatment. One case did not receive relevant treatment prior to death. Relevant treatment was defined as treatment against a known etiology or empirical treatment as per local guideline for suspected bacterial meningitis or invasive meningococcal disease.
4.5 h. There were 2 cases in this group that did not survive, while 1 case died before receiving any antibiotic treatment.

Thirty-day mortality was 11% (4/38) and all fatalities occurred within the first 24 h from initial contact.

Discussion

Early suspicion and identification of cases with IMD was difficult because symptoms were diverse and nonspecific at the initial contact to the EMS. The most common symptom was fever, while specific symptoms associated with IMD were less frequently confirmed to be present and were rarely mentioned or asked about during the initial contact to the EMS. Symptoms differed by age suggesting that age-guided questioning may be relevant. While some specific symptoms have a high specificity for severe infections, patients presenting with nonspecific symptoms can have a noteworthy risk of short-term mortality across a broad spectrum of conditions [14, 15]. While all feverish cases should be asked about specific symptoms, such as rashes, headache, stiffness of the neck and strong leg pain, cases younger than 18 years of age with fever and a rash require additional attention and should be cautioned of symptoms and signs suggestive of progression and general worsening of their condition. In contrast, older individuals more often reported difficulty breathing. We acknowledge that fever and rash in children and adolescents occur frequently due to several mainly viral etiologies. Similarly, difficulty of breathing is a frequent symptom among adults.

Larger cohorts and further research are warranted to identify patterns of early presenting symptoms that may better discriminate individuals with a high likelihood of IMD. Current literature on this subject is very limited, especially among adults. Our findings elaborate the current knowledge about how nonspecific symptoms dominate at early stages of IMD, but our data also indicate that cases with IMD progress rapidly to life-threatening disease, as all cases were hospitalized within 12 h, regardless of which symptoms they presented with. When assessing a febrile child, general practitioners rarely consider BM or IMD as likely causes and prehospital penicillin is mainly given if the diagnosis of meningitis or septicaemia is thought to be certain [16]. Conflicting data have been reported about the effects of prehospital antibiotic treatment which may be because the antibiotics more often were given to patients with more severe IMD and thus higher risk of bad outcome [17]. However, more recent studies have found that prehospital antibiotics can be protective against death from IMD and that it is a safe treatment, even though more data is needed to either recommend or reject the use of it [18, 19]. We believe that relevant treatment should be initiated as soon as possible when suspecting a time critical condition such as IMD.

We suggest that all healthcare workers, such as general practitioners and EMS-workers, who may have early contact to feverish patients consider IMD even when specific symptoms are absent. It is important to keep in mind that not all cases of IMD have BM, thus ruling out BM does not rule out IMD. In addition, we suggest that feverish patients who are not suspected for IMD are informed about specific symptoms and are encouraged to contact medical services again if their symptoms progress, especially within the first 12 h from the initial contact. A study has shown that in children with IMD parents often found their children's behavior and the course of the disease to be different from previous illnesses [20], thus it is important to include their perception when considering diagnoses in febrile children.

The main limitations of this study are the modest sample size and the fact that symptoms may have been present during the initial contact to emergency medical services even if they were not asked about. This limits our ability to perform statistical analyses, but we do believe that the general picture of symptoms in this study is representable for how cases with IMD present at first contact to EMS. The structure of acute healthcare systems varies across the world, thus cases with IMD may present differently in other countries. We believe that we were able to include most cases with IMD in our analysis because we used very broad criteria for screening as indicated by the many excluded cases. We may have missed cases due to prehospital deaths from IMD. However, all forensic autopsies are performed on unexpected deaths in Denmark, which may have led to findings of meningococci. Thus, we find it unlikely that cases were missed.

We present novel unique information of all stages of IMD from initial EMS calls to outcome. This method could be introduced for larger populations where similar data is available and for other diseases where the initial handling of the disease is vital for outcome, such as BM.

Abbreviations

BM: Bacterial meningitis; EHR: Electronic health record; EMS: Emergency medical services; IMD: Invasive meningococcal disease.

Acknowledgements

The authors wish to thank the Patient Safety Group at the Capital Region of Denmark working with meningitis and invasive meningococcal disease.

Case and public involvement statement

Four relatives to cases with meningococcal disease were part of the task force working with meningococcal disease in the Capital Region of Denmark that initiated this study. They participated in the selection of the study's aim and methods. Cases and the public were not involved in collection, analysis, and interpretation of the data.
Permissions
No third-party material was used in this manuscript.

Authors’ contributions
NH, HCC, LFL, PD, JA, ATB, and TB conceived and designed the study. NH, HCC, JA, SNF in ATB collected the data. NH and HS contributed to data analysis. NH, HCC, LFL and HS wrote the manuscript. NH, LCC, LFL, G, SNF and TB contributed to data interpretation. All authors critically reviewed and approved the final version of the manuscript.

Funding
There are no funding sources for this study.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval
Permission to collect data from case records was granted by Center for Health and by Emergency Medical Services in the Capital Region of Denmark as required by Danish legislation. All data was handled according to GDPR-rules. As this was a quality development project, the Committee on Health Research Ethics were not involved in approving data collection, handling, or publication.

Consent for publication
Not applicable.

Competing interests
Nicholas Hovmand has nothing to disclose.
Helle Collatz Christensen has nothing to disclose.
Lene Fogt Lundbo has nothing to disclose.
Jørgen Sandholdt has nothing to disclose.
Gitte Kronborg has nothing to disclose.
Perle Dansø has nothing to disclose.
Jacob Anhøj has nothing to disclose.
Stig Nikolaj Farmer Blomberg has nothing to disclose.
Asmus Thun Bisgaard has nothing to disclose.
Thomas Benfield reports grants from Nova Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, and personal fees from Gilead, personal fees from MSD.

Author details
1 Center for Research & Disruption of Infectious Diseases (CREDID), Department of Infectious Diseases, Copenhagen University Hospital – Armaer og Hvidovre, Kettegaard Alle 30, 2650 Hvidovre, Denmark. 2 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3 Emergency Medical Services, Capital Region of Denmark, Telegrafvej 5, 2730 Ballerup, Denmark. 4 Department of Infectious Diseases, Copenhagen University Hospital – Armaer and Hvidovre, Kettegaard Alle 30, 2650 Hvidovre, Denmark. 5 Center for Health, Capital Region of Denmark, Kongens Vaereng 2, 3400 Hillerød, Denmark. 6 Diagnostic Center, Copenhagen University Hospital – Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Received: 12 May 2021  Accepted: 11 November 2021  Published online: 30 November 2021

References
1. Pearce J, Peters M, May N, et al. Care of the patient with invasive meningococcal disease by prehospital emergency medical service clinicians: a scoping review. BMJ Open 2020;10:e033447. doi:https://doi.org/10.1136/bmjopen-2019-033447
2. Haj-Hassan TA, Thompson MJ, Mayon-White RT, et al. Which early ‘red flag’ symptoms identify children with meningococcal disease in primary care? Br J Gen Pract 2011;61:e97–104. doi:https://doi.org/10.3399/bjgp11X561131
3. Hodgetts TJ, Brett A, Castle N. The early management of meningococcal disease. J Accid Emerg Med 1998;15:72–6. doi:https://doi.org/10.1136/ emj.15.2.72
4. Okike IO, Ladhani SN, Anthony M, et al. Assessment of healthcare delivery in the early management of bacterial meningitis in UK young infants: an observational study. BMJ Open 2017;7:e015700. doi:https://doi.org/10.1136/bmjopen-2016-015700
5. Domingo P, Pomar V, Mauri A, et al. Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. Lancet Infect Dis 2019;19:e284–94. doi:https://doi.org/10.1016/S1473-3099(19)30040-4
6. Hart CA, Thomson AJ. Meningococcal disease and its management in children. BMJ 2006;333:685–90. doi:https://doi.org/10.1136/bmj.38968.683958.AE
7. Okike IO, Ribeiro S, Ramsay ME, et al. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study. Lancet Infect Dis 2014;14:301–7. doi:https://doi.org/10.1016/S1473-3099(13)70332-3
8. Oordt-Speets AM, Bolijn R, van Hoorn RC, et al. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS ONE 2018;13(e0198772). doi:https://doi.org/10.1371/journal.pone.0198772
9. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001;344:1378–88. doi:https://doi.org/10.1056/NEJM200105033441807
10. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006;367:397–403. doi:https://doi.org/10.1016/S0140-6736(06)67367-1
11. Nadel S, Ditto J, Booy R, et al. Avoidable deficiencies in the delivery of health care to children with meningococcal disease. J Accid Emerg Med 1998;15:298–303. doi:https://doi.org/10.1136/ emj.15.5.298
12. Beebeejaun K, Parikh SR, Campbell H, et al. Invasive meningococcal disease: Timing and cause of death in England, 2008-2015. J Infect 2020;80:286–90. doi:https://doi.org/10.1016/j.jinf.2019.12.008
13. Danish Health Care Act §42 D. https://danskeloven.dk/sundhedsloven/42d
14. Karakoumis J, Nickel CH, Kirch M, et al. Emergency Presentations With Nonspecific Complaints—the Burden of Morbidity and the Spectrum of Underlying Disease: Nonspecific Complaints and Underlying Disease. Medicine (Baltimore) 2015;94:8.e40. doi:https://doi.org/10.1097/MD.0000000000000840
15. Van den Brul A, Aertgeerts B, Bruyninckx R, et al. Signs and symptoms for diagnosis of serious infections in children: a prospective study in primary care. Br J Gen Pract 2007;57:538–46.
16. Brennan CA, Somerset M, Granier SK, et al. Management of diagnostic uncertainty in children with possible meningitis: a qualitative study. Br J Gen Pract 2003;53:626–31.
17. Nadel S, Kroll JS. Diagnosis and management of meningococcal disease: the need for centralized care. Fam Med 2007;39:1–8. doi:https://doi.org/10.1233/FM.2006-0059x
18. Sudarsanam TD, Rupali P, Taljaard M, et al. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst Rev 2017;6:CD005437. doi:https://doi.org/10.1002/14651858.CD005437.pub4
19. Cabellos C, Pelegrin I, Benavent E, et al. Impact of pre-hospital antibiotic therapy on mortality in invasive meningococcal disease: a propensity score study. Eur J Clin Microbiol Infect Dis 2019;38:1671–6. doi:https://doi.org/10.1007/s10096-019-03599-8
20. Van den Brul A, Bruyninckx R, Vermeeir E, et al. Signs and symptoms in children with a serious infection: a qualitative study. BMC Fam Pract 2005;6:36. doi:https://doi.org/10.1186/1471-2296-6-36

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.